share_log

同和药业(300636.SZ):2024全年CMO/CDMO业务收入同比减少较多

Jiangxi Synergy Pharmaceutical (300636.SZ): The revenue from CMO/CDMO Business in 2024 is expected to decrease significantly compared to the previous year.

Gelonghui Finance ·  Jan 8 17:27

Gelonghui, January 8 - Jiangxi Synergy Pharmaceutical (300636.SZ) recently stated in an investor relations event that a major original research client canceled all Orders from the second quarter and thereafter, leading to a significant year-on-year decrease in CMO/CDMO Business revenue for the whole year. In 2025, some new projects in this Sector will launch, and revenue is expected to be higher than in 2024.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment